Journal of Clinical Oncology
Articles in this Issue
PRISM: A transparent, self-correcting LLM system for reproducible therapy recommendations in neuroendocrine tumors.
e13657 Background: The clinical application of Large Language Models (LLMs) in oncology is currently limited by opaque rea...
Brain radiotherapy and risk of wound healing following Ommaya reservoir placement in leptomeningeal disease (LMD).
e13579 Background: Leptomeningeal disease (LMD) is a late-stage sequelae of solid and hematologic disease progression. Dev...
Efficacy and safety of the pertuzumab biosimilar BCD-178 versus the originator pertuzumab in patients with HER2-positive locally advanced breast cancer: Results from the international, double-blind, randomized, phase III PREFER trial.
613 Background: Pertuzumab, a HER2-targeting monoclonal antibody, significantly improves outcomes for patients with HER2-p...
Prospective, randomized, placebo-controlled phase 2b trial of SurVaxM plus adjuvant temozolomide in newly diagnosed glioblastoma (SURVIVE).
TPS2106 Background: Survivin is widely expressed in glioblastoma (GBM) and is implicated in tumor cell survival and treatm...
Machine learning–based prognostic models for mortality prediction after unplanned hospitalization in cancer patients.
11122 Background: Unplanned hospitalizations in oncology patients often indicate acute clinical deterioration and are asso...
Trends and disparities in lung cancer and atrial fibrillation/flutter–related mortality in the United States, 2000–2023.
e23367 Background: Lung cancer remains a leading cause of mortality among U.S. adults, frequently complicated by cardiovas...
Pharmacokinetics and pharmacodynamics of the GCN2 activator HC-7366 in a phase 1a study in patients with advanced solid tumors.
e15103 Background: HC-7366 is a novel, selective and potent activator of general control nonderepressible 2 (GCN2), a core...
COPERNICUS, a pragmatic phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) + lazertinib (laz) with supportive care in <i>EGFR</i> -mutated advanced NSCLC: Early safety results.
8613 Background: In MARIPOSA, intravenous (IV) ami + laz significantly prolonged overall survival vs osimertinib (HR, 0.75...
Evaluation of genomic DNA stability and white blood cell integrity in TFLB and Streck blood collection tubes for oncology diagnostics application.
e22563 Background: Reliable stabilization of genomic DNA (gDNA) and cellular integrity is critical for oncology clinical t...
Structural mimicry of the TOP1 cleavage complex by intratumoural bacterial proteins as a possible mechanism for geographical variation in TOP1 inhibitor efficacy in non-small cell lung cancer.
e15039 Background: We previously demonstrated that microbiome-derived proteins with sequence homology to human topoisomera...
Discovery of gene set–based biomarkers and therapeutic targets for papillary thyroid cancer based on circulating DNA and tissue RNA.
6074 Background: Mutations in pathways known to promote oncogenesis in Papillary Thyroid Carcinoma (PTC) have been demonst...
Anti–PD-(L)1 plus chemotherapy in advanced PD-L1–negative nonsquamous non–small cell lung cancer: A systematic review and meta-analysis.
e20580 Background: Nonsquamous non-small cell lung cancer (nsqNSCLC) accounts for approximately 70–80% of all non-small ce...
Artificial intelligence–guided microsatellite instability classification in colorectal cancer (CRC): EfficientNet-based histopathology analysis for precision treatment planning.
e15621 Background: Microsatellite instability (MSI) represents a biomarker in CRC, affecting 15–20% of cases and guiding t...
Fruquintinib in combination with tislelizumab vs trifluridine/tipiracil and bevacizumab in MSS mCRC without active liver metastases: The IKF-080/QUINTIS trial.
TPS3684 Background: Patients with metastatic colorectal cancer (mCRC) who progress after treatment with fluoropyrimidines,...
Outcomes with androgen-deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPIs) in veterans with de novo metastatic castration-sensitive prostate cancer (mCSPC) who were elderly, frail, or had high comorbidity: A subgroup analysis of enzalutamide and high-volume disease.
5094 Background: Clinical trials show significant overall survival (OS) benefits of combining ADT with ARPIs (abiraterone,...
Biological subtype discordance after neoadjuvant therapy in early breast cancer: Findings from a 1,500-patient cohort with residual disease.
604 Background: Although biomarker reassessment is standard in recurrent breast cancer, its role in early breast cancer wi...
Phase II trial of pembrolizumab in combination with odetiglucan for patients with metastatic colorectal adenocarcinoma with liver-predominant disease.
TPS3673 Background: Liver metastases are associated with resistance to immune checkpoint inhibitors in patients with misma...
A phase II trial of lenvatinib plus pembrolizumab in patients (pts) with endometrial or ovarian carcinosarcoma.
5615 Background: Carcinosarcoma is a rare and aggressive histology of gynecologic carcinomas that has limited treatment op...
Moving the surgical prostate cancer treatment to value: Early results in patient-reported outcomes from a Brazilian cohort.
e13601 Background: Prostate cancer (PCa) is the most frequently diagnosed malignancy among men in Brazil. While therapeuti...
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring the rare <i>KRAS</i> codon 12 mutations G12A, G12S, G12R, and G12F.
e20647 Background: KRAS mutations occur in approximately 30% of non-small cell lung cancers (NSCLC) an...
Plasma levels of mitochondrial gene copy number and microRNA transcripts as effective minimally invasive biomarkers for endometrial adenocarcinoma.
e17629 Background: The development of endometrial adenocarcinoma (EA) is linked to aberrations in the mitochondrial genome...
Camrelizumab combined with liposomal doxorubicin and dacarbazine as first-line therapy for advanced, recurrent, and metastatic undifferentiated pleomorphic sarcoma: A phase II study.
11513 Background: This phase II study aims to evaluate the efficacy and safety of camrelizumab combined with liposomal dox...
A phase II, multi-cohort study with pemetrexed plus cisplatin combination in patients with relapsed or refractory advanced soft tissue sarcoma: Leiomyosarcoma cohort (ALBATROSS-SARC-LMS01).
11559 Background: Given the promising results in previous single arm trial (NCT03809637), this histology-specific, multi-c...
Clinical and economic outcomes associated with inpatient palliative care in hospitalized patients with cancer: A systematic review and meta-analysis.
e24072 Background: Inpatient palliative care (IPC) is increasingly utilized for hospitalized patients with cancer to impro...
Perioperative SHR-A2102, a novel nectin-4–targeted antibody-drug conjugate, in combination with adebrelimab for patients (pts) with muscle-invasive bladder cancer: Results from a phase 2/3 study.
4506 Background: Muscle-invasive bladder cancer (MIBC) is an aggressive disease, with substantial recurrence risk after ra...